AI Engines For more Details: Perplexity Kagi Labs You
Antiepileptic Effects: Vigabatrin is classified as an antiepileptic drug (AED) and works by increasing the levels of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits the excitability of neurons in the brain. By enhancing GABA levels, vigabatrin helps to stabilize neural activity and prevent seizures.
Treatment of Epilepsy: Vigabatrin is indicated for use as adjunctive therapy (in combination with other antiepileptic medications) in the treatment of refractory complex partial seizures (CPS) in adults and children who have not responded adequately to other treatments. It is also used as monotherapy (alone) for infantile spasms (also known as West syndrome) in infants and young children.
Infantile Spasms: Vigabatrin is particularly effective in the treatment of infantile spasms, a rare and severe form of epilepsy that typically manifests during infancy or early childhood. By suppressing spasms and improving seizure control, vigabatrin may help reduce the frequency and severity of these episodes.
Mechanism of Action: Vigabatrin exerts its antiepileptic effects by irreversibly inhibiting the enzyme GABA transaminase (also known as GABA-T), which is responsible for the breakdown of GABA in the brain. By blocking GABA-T, vigabatrin increases the availability of GABA, leading to enhanced inhibitory neurotransmission and reduced neuronal excitability.
Visual Field Defects: One of the most significant side effects associated with vigabatrin use is the risk of irreversible peripheral vision loss, known as bilateral concentric visual field constriction. This adverse effect occurs in a subset of patients treated with vigabatrin and is dose-dependent. Regular monitoring of visual function is essential during vigabatrin therapy to detect any changes in visual fields promptly.
Seizure Control: Vigabatrin has been shown to be effective in controlling seizures in many patients with epilepsy, particularly those with refractory or difficult-to-treat seizures. It may help reduce the frequency, duration, and intensity of seizures, leading to improved seizure management and quality of life.
Dosing and Administration: Vigabatrin is typically administered orally in the form of tablets or powder for oral solution. The dosage and administration schedule may vary depending on the patient's age, weight, medical history, and seizure type. Healthcare providers will carefully titrate the dose to achieve optimal seizure control while minimizing the risk of adverse effects.
Clinical Monitoring: Patients receiving vigabatrin therapy require regular monitoring to assess treatment response, evaluate seizure frequency and severity, and detect any potential adverse effects, particularly visual field defects. Ongoing communication between patients, caregivers, and healthcare providers is essential for optimizing treatment outcomes and ensuring patient safety.
Drug Interactions: Vigabatrin may interact with other medications, including other antiepileptic drugs, potentially affecting their efficacy or safety profiles. Healthcare providers should review the patient's complete medication regimen to identify and manage any potential drug interactions appropriately.
Patient Education: Patients and caregivers should receive comprehensive education regarding vigabatrin therapy, including proper dosing instructions, potential side effects, the importance of adherence to treatment, and the need for regular monitoring. They should be encouraged to report any new or worsening symptoms promptly to their healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.4 | 0.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergies | 0.1 | -0.1 | |
| Alzheimer's disease | 0.1 | 1.5 | -14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.1 | 1 |
| Anorexia Nervosa | 0.4 | -0.4 | |
| Antiphospholipid syndrome (APS) | 0.1 | -0.1 | |
| Asthma | 0.3 | -0.3 | |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 0.2 | 0.1 | 1 |
| Autism | 0.8 | 0.8 | 0 |
| Bipolar Disorder | 0.1 | 0.1 | 0 |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.1 | 0.1 | |
| Celiac Disease | 0.1 | -0.1 | |
| Cerebral Palsy | 0.1 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 0.4 | 0.4 | |
| Chronic Kidney Disease | 0.2 | 0.6 | -2 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | -0.1 | |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Colorectal Cancer | 0.1 | 0.2 | -1 |
| Constipation | 0.1 | -0.1 | |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 0.1 | 1 | -9 |
| Crohn's Disease | 0.3 | 0.6 | -1 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 0.8 | 1 | -0.25 |
| Epilepsy | 0.1 | 0.2 | -1 |
| Fibromyalgia | 0.1 | 0.1 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | -0.3 | |
| gallstone disease (gsd) | 0.1 | -0.1 | |
| Graves' disease | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.4 | 0.1 | 3 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.3 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.2 | -0.2 | |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.1 | 0.5 | -4 |
| Hypoxia | 0.1 | 0.1 | |
| Inflammatory Bowel Disease | 1 | -1 | |
| Insomnia | 0.1 | -0.1 | |
| Irritable Bowel Syndrome | 0.2 | 0.2 | 0 |
| Liver Cirrhosis | 0.3 | 0.3 | 0 |
| Long COVID | 0.6 | 0.4 | 0.5 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.1 | -0.1 | |
| ME/CFS with IBS | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.3 | 0.6 | -1 |
| Mood Disorders | 1 | 1 | 0 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.2 | 0.6 | -2 |
| Multiple system atrophy (MSA) | 0.4 | 0.4 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | -0.6 | |
| Obesity | 0.7 | 0.2 | 2.5 |
| obsessive-compulsive disorder | 0.5 | -0.5 | |
| Osteoporosis | 0.1 | -0.1 | |
| Parkinson's Disease | 0.2 | 0.4 | -1 |
| Polycystic ovary syndrome | 0.2 | -0.2 | |
| Psoriasis | 0.1 | 0.2 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.1 | 2 |
| Rosacea | 0.2 | 0.1 | 1 |
| Schizophrenia | 0.2 | 0.1 | 1 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.2 | -0.2 | |
| Sleep Apnea | 0.1 | -0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.2 | 0 |
| Systemic Lupus Erythematosus | 0.1 | 0.1 | 0 |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.1 | 0.1 | 0 |
| Type 2 Diabetes | 0.3 | 0.3 | 0 |
| Ulcerative colitis | 0.4 | -0.4 | |
| Unhealthy Ageing | 0.6 | 0.6 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.